CompletedNCT01107496
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
Researchers compared IR Viloxazine and placebo, tracking side effects to assess safety and tolerability in adults with ADHD.
Medication studyAges 18–64United States
Understand this study
What did researchers investigate?
Researchers compared IR Viloxazine and placebo, tracking side effects to assess safety and tolerability in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Bradenton, United States · Libertyville, United States and 2 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 52
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT01107496
- Official title
Show the full official title
A Phase I/IIa Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Immediate-Release Viloxazine in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedBradenton · Libertyville · Owensboro
1 more locations
- Herndon
Questions about this study
What did researchers investigate?
Researchers compared IR Viloxazine and placebo, tracking side effects to assess safety and tolerability in adults with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including IR Viloxazine and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
United States
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
United States